Attached files
| file | filename |
|---|---|
| 10-K - 10-K - CTI BIOPHARMA CORP | cti10k12312016document.htm |
| EX-31.2 - EXHIBIT 31.2 - CTI BIOPHARMA CORP | a2016exhibit312sect302cert.htm |
| EX-31.1 - EXHIBIT 31.1 - CTI BIOPHARMA CORP | a2016exhibit311sect302cert.htm |
| EX-23.1 - EXHIBIT 23.1 - CTI BIOPHARMA CORP | a2016exhibit231accountingf.htm |
| EX-21.1 - EXHIBIT 21.1 - CTI BIOPHARMA CORP | a2016exhibit21110kfy2016su.htm |
| EX-12.1 - EXHIBIT 12.1 - CTI BIOPHARMA CORP | a2016exhibit121ratioofearn.htm |
Exhibit 32
CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES‑OXLEY ACT OF 2002
I, Richard L. Love, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002, that the Annual Report of CTI BioPharma Corp. on Form 10‑K for the fiscal year ended December 31, 2016 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10‑K fairly presents in all material respects the financial condition and results of operations of CTI BioPharma Corp.
A signed original of this written statement required by Section 906 has been provided to CTI BioPharma Corp. and will be retained by CTI BioPharma Corp. and furnished to the Securities and Exchange Commission or its staff upon request.
Dated: March 2, 2017 | By: /s/ Richard L. Love |
Richard L. Love | |
Interim President and Chief Executive Officer | |
I, Louis A. Bianco, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002, that the Annual Report of CTI BioPharma Corp. on Form 10‑K for the fiscal year ended December 31, 2016 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10‑K fairly presents in all material respects the financial condition and results of operations of CTI BioPharma Corp.
A signed original of this written statement required by Section 906 has been provided to CTI BioPharma Corp. and will be retained by CTI BioPharma Corp. and furnished to the Securities and Exchange Commission or its staff upon request.
Dated: March 2, 2017 | By: /s/ Louis A. Bianco |
Louis A. Bianco | |
Executive Vice President | |
Finance and Administration | |